MX2022010373A - Vacuna contra el virus de la peste porcina africana. - Google Patents

Vacuna contra el virus de la peste porcina africana.

Info

Publication number
MX2022010373A
MX2022010373A MX2022010373A MX2022010373A MX2022010373A MX 2022010373 A MX2022010373 A MX 2022010373A MX 2022010373 A MX2022010373 A MX 2022010373A MX 2022010373 A MX2022010373 A MX 2022010373A MX 2022010373 A MX2022010373 A MX 2022010373A
Authority
MX
Mexico
Prior art keywords
swine fever
african swine
virus infection
fever virus
vaccine against
Prior art date
Application number
MX2022010373A
Other languages
English (en)
Inventor
Simon Davis
Linda Dixon
Ana Reis
Yuan Jenq Lui
Shinji Ikemizu
Original Assignee
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by The Pirbright Inst filed Critical The Pirbright Inst
Publication of MX2022010373A publication Critical patent/MX2022010373A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a virus de la peste porcina africana atenuados. Los virus atenuados protegen a los cerdos contra la exposición posterior a virus virulentos. La presente invención también se refiere al uso de los virus atenuados para tratar y/o prevenir la peste porcina africana.
MX2022010373A 2020-03-06 2021-03-05 Vacuna contra el virus de la peste porcina africana. MX2022010373A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050560 WO2021176234A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
MX2022010373A true MX2022010373A (es) 2023-01-19

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010373A MX2022010373A (es) 2020-03-06 2021-03-05 Vacuna contra el virus de la peste porcina africana.
MX2022010372A MX2022010372A (es) 2020-03-06 2021-03-05 Vacuna contra la infeccion por el virus de la peste porcina africana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010372A MX2022010372A (es) 2020-03-06 2021-03-05 Vacuna contra la infeccion por el virus de la peste porcina africana.

Country Status (12)

Country Link
US (3) US20230124042A1 (es)
EP (3) EP4114454A1 (es)
JP (2) JP2023516713A (es)
KR (2) KR20230013016A (es)
CN (3) CN116133680A (es)
AU (2) AU2021231402A1 (es)
BR (2) BR112022016891A2 (es)
CA (2) CA3170043A1 (es)
CL (2) CL2022002416A1 (es)
CO (2) CO2022014152A2 (es)
MX (2) MX2022010373A (es)
WO (3) WO2021176236A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031045A2 (en) * 2022-08-04 2024-02-08 Malcolm Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
EP4114454A1 (en) 2023-01-11
KR20230013017A (ko) 2023-01-26
WO2021176235A1 (en) 2021-09-10
EP4114455A1 (en) 2023-01-11
CO2022014152A2 (es) 2023-02-16
CN115605223A (zh) 2023-01-13
KR20230013016A (ko) 2023-01-26
WO2021176234A1 (en) 2021-09-10
US20240293525A1 (en) 2024-09-05
EP4114453A1 (en) 2023-01-11
BR112022016891A2 (pt) 2023-01-24
US20230117978A1 (en) 2023-04-20
CA3170043A1 (en) 2021-09-10
WO2021176236A1 (en) 2021-09-10
CA3170058A1 (en) 2021-09-10
CN115397463A (zh) 2022-11-25
CN116133680A (zh) 2023-05-16
MX2022010372A (es) 2023-01-19
BR112022016893A2 (pt) 2023-01-24
CL2022002412A1 (es) 2023-03-03
CO2022014256A2 (es) 2022-12-30
AU2021229654A1 (en) 2022-11-03
BR112022016893A8 (pt) 2023-02-28
JP2023516713A (ja) 2023-04-20
AU2021231402A1 (en) 2022-11-03
CL2022002416A1 (es) 2023-03-03
US20230124042A1 (en) 2023-04-20
JP2023516709A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
MX2022010373A (es) Vacuna contra el virus de la peste porcina africana.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
EA201990085A1 (ru) Рационально разработанный аттенуированный штамм вируса африканской лихорадки свиней для защиты от заражения исходным вирусным изолятом georgia 2007
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
MX2017013956A (es) Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2023007395A (es) Vacunas del virus de la peste porcina africana (ppa).
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
MY187896A (en) Dengue virus vaccine compositions and methods of use thereof
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
BR112023019841A2 (pt) Vacina contra vírus da pseudorraiva
MX2021015938A (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino.
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
PH12021550987A1 (en) Anti-rabies monoclonal antibodies and cocktail thereof